Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Decitabine and Venetoclax in TP53-Mutated AML
NCT04277442Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Primary endpoints: Incidence of Adverse Events, Number of Patients That Are Able to Complete 3 Cycles of Therapy and 1 more. Started Mar 2020; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04277442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04277442.